ライフサイエンスコーパス: pharmacogenomic

1 ic basis of disease and drug response (i.e., pharmacogenomics).

2 odules, with direct implications to clinical pharmacogenomics.

3 ing the realization of the full potential of pharmacogenomics.

4 impact and evolving evidence for clopidogrel pharmacogenomics.

5 at remain for the clinical implementation of pharmacogenomics.

6 o be important in disease susceptibility and pharmacogenomics.

7 interventions and assessing cancer risk and pharmacogenomics.

8 l applications in both genetic screening and pharmacogenomics.

9 genetic profiling studies), and host-related pharmacogenomics.

10 ll molecules and have clear implications for pharmacogenomics.

11 ic gene variants for medical diagnostics and pharmacogenomics.

12 genetic information, an application known as pharmacogenomics.

13 nge is how to use these data effectively for pharmacogenomics.

14 functional approaches and model systems, and pharmacogenomics.

15 atabase with direct implications in clinical pharmacogenomics.

16 n-induced pluripotent stem cells and systems pharmacogenomics accelerate future studies of precision

17 Pharmacogenomics addresses this issue by seeking to iden

18 drug-gene interaction analysis identified a pharmacogenomic agent that preferentially interacted wit

19 tions in drug-metabolizing enzymes and other pharmacogenomic alterations, may have more pronounced ef

20 Pharmacogenomic analyses identified molecular markers of

21 cessful and highlights the need for detailed pharmacogenomic analyses of CS mutations.

22 Planned translational research and pharmacogenomic analyses of tumor and blood samples may

23 rdingly offer the promise of haplotyping and pharmacogenomic analysis directly in double-stranded DNA

24 hanisms of resistance to MEKi, we employed a pharmacogenomic analysis of MEKi-sensitive versus MEKi-r

25 Analysis (Xeva) software tool that empowers pharmacogenomic analysis through integration of PDX mode

26 In the pharmacogenomic analysis, rs62298861 and rs28365062 in t

27 Through machine learning based integrative pharmacogenomic analysis, the microRNA biomarkers identi

28 medications have not been subject to proper pharmacogenomic analysis.

29 ingle 35-mg/kg dose of oral deferasirox; and pharmacogenomic analysis.

30 atome(TM) will accelerate clinical, genomic, pharmacogenomic and advanced translational research in o

31 conventional genetic markers and can provide pharmacogenomic and biologic insight into the pathophysi

32 Here, we integrate pharmacogenomic and clinical data with a human metabolic

33 position, screening, diagnostic, prognostic, pharmacogenomic and monitoring markers.

34 lthough exploratory in nature, this combined pharmacogenomic and pharmacokinetic model helps to defin

35 determination and interpretation of TSPs in pharmacogenomic and toxicogenomic studies that examine t

36 an application of functional neuroimaging in pharmacogenomics and extend basic evidence of an inverte

37 A review of pharmacogenomics and how it affects the response to anal

38 wledge embedded in vast amounts of available pharmacogenomics and omics data.

39 developments in the field of cardiovascular pharmacogenomics and personalized medicine.

40 In the future, pharmacogenomics and point-of-care testing will likely p

41 Data from the Pharmacogenomics and Risk of Cardiovascular Disease (PAR

42 We discuss the implications for pharmacogenomics and the uncharted complexity in genotyp

43 is review will focus on pharmacogenetics and pharmacogenomics and their role in reducing ADRs, especi

44 level, the relationship between transporter pharmacogenomics and therapeutics in the age of individu

45 sed test to a sequencing study in anticancer pharmacogenomics and uncovered mechanistic insights into

46 fficiency may have important consequences in pharmacogenomics and variable drug toxicity observed in

47 ociation between genetics and drug response (pharmacogenomics) and the association of sequence variat

48 ase-causing variants, cardiovascular-related pharmacogenomics, and carrier status for recessive disea

49 tion based on patients' pharmacodynamics and pharmacogenomics, and improved supportive care.

50 he NOS1AP gene may have relevance for future pharmacogenomic applications in clinical practice permit

51 In contrast, the benefits of pharmacogenomic applications such as the identification

52 with experimental medications in humans; the pharmacogenomics applied to these medications and disord

53 This pharmacogenomic approach led us to identify two pathways

54 populations, is needed before the role of a pharmacogenomic approach to oral anticoagulation therapy

55 A pharmacogenomic approach to warfarin dosing has the pote

56 propose here a new integrative computational pharmacogenomic approach, referred to as Drug Network Fu

57 easing recognition of the limitations of the pharmacogenomic approach, which does not take account of

58 Pharmacogenomic approaches are emerging across broad cla

59 iscuss the potential of systems genetics and pharmacogenomic approaches for the development of antimy

60 ntial utility in patient stratification, and pharmacogenomics approaches.

61 Systems pharmacology and pharmacogenomics are emerging to exploit the available d

62 Genomics and pharmacogenomics are signalling the start of a new era f

63 e genotyped for 7907 variants using a custom pharmacogenomic array.

64 ns administered at 12 and 24 months, and the pharmacogenomic assessment of AMD Gene Consortium-identi

65 We sought pharmacogenomic association of long, short, and heterozy

66 rmacologically annotated and explore dynamic pharmacogenomic associations against 37 molecularly targ

67 to anti-VEGF treatment, however to date, no pharmacogenomic associations have been consistently iden

68 rdles that need to be overcome as we explore pharmacogenomic associations specifically in the field o

69 Strategies for uncovering pharmacogenomic associations vary widely from monogenic

70 RECENT FINDINGS: Previously recognized pharmacogenomic associations with drug efficacy have bee

71 with Mendelian disorders), carrier variants, pharmacogenomic associations, and polygenic risk estimat

72 Pharmacogenomics attempts to elucidate the inherited bas

73 ic strategies, particularly patient-specific pharmacogenomics-based therapy, with monitoring of thera

74 d and Drug Administration (FDA) and required pharmacogenomic biomarker testing, we describe 1) the us

75 nerabilities and prioritization of potential pharmacogenomics biomarkers for development of personali

76 ntify potential network-based diagnostic and pharmacogenomics biomarkers from large-scale scRNA-seq p

77 dual patients' scRNA-seq data can be used as pharmacogenomics biomarkers to predict drug responses (T

78 ts leading mostly to monogenic disorders and pharmacogenomics biomarkers.

79 ut microenvironment, gut-brain interactions, pharmacogenomics, biopsychosocial, gender and cross cult

80 We cover the practical applications of pharmacogenomics both in the pharmaceutical industry and

81 In drug discovery, pharmacogenomics can be used to aid lead identification,

82 namic properties of pharmacological systems, pharmacogenomics can now provide an objective measure of

83 as a foundation for further research on how pharmacogenomics can reduce the incidence of adverse rea

84 A pharmacogenomics characterization of mithramycin-induced

85 nt of epilepsy, epigenetic determinants, and pharmacogenomics comes the hope for better, disease-modi

86 e publicly available International Tamoxifen Pharmacogenomics Consortium (ITPC) dataset.

87 URPOSE To explore whether population-related pharmacogenomics contribute to differences in patient ou

88 Furthermore, we identify pharmacogenomic correlations between specific variants i

89 This study demonstrates how pharmacogenomic data can be used to systematically ident

90 Here we analyzed proteomic and pharmacogenomic data in cancer tissues and cell lines us

91 Given the recent large scale of available pharmacogenomic data, it is possible to systematically i

92 new avenues of research for meta-analysis of pharmacogenomic data.

93 -cancer drugs and gene mutations using DI in pharmacogenomic data.

94 we report the integration of multi-omics and pharmacogenomics data across large-scale patient samples

95 a (CCLE) study as the benchmark dataset, all pharmacogenomics data exhibited their roles in inferring

96 based on integration of the heterogeneously pharmacogenomics data from both cell and drug sides.

97 Computational analysis of cancer pharmacogenomics data has resulted in biomarkers predict

98 ach topic, we summarize current genomics and pharmacogenomics data resources such as pan-cancer genom

99 integrative analysis of preclinical in vivo pharmacogenomics data to identify biomarkers predictive

100 By analyzing existing pharmacogenomics data, we propose the potential design o

101 acterize and learn from rapidly accumulating pharmacogenomics data.

102 have seen an increase in the availability of pharmacogenomic databases such as Genomics of Drug Sensi

103 igating the correspondence between different pharmacogenomics databases and discuss the potential fac

104 We demonstrate how to integrate pharmacogenomics databases through integration of the bi

105 ried disease-specific mutation databases and pharmacogenomics databases to identify genes and mutatio

106 Samples collected in pharmacogenomics databases typically belong to various c

107 mation is currently distributed over several pharmacogenomics databases.

108 Using the largest PDX pharmacogenomic dataset to date, we identified 87 pathwa

109 an open-source software package for in vivo pharmacogenomic datasets that allows for quantification

110 package for integrative analysis of multiple pharmacogenomic datasets.

111 thotrexate solidifies the robustness of this pharmacogenomic determinant of methotrexate clearance.

112 iants of SLCO2B1 and SLCO1B3 may function as pharmacogenomic determinants of resistance to ADT in pro

113 Although pharmacogenomic differences may explain some of these di

114 Pharmacogenomic discoveries are also likely to lead to m

115 Moreover, pharmacogenomic discoveries show promise as important el

116 ew will place in context clinically relevant pharmacogenomic discovery approaches, including the rela

117 nd provides a widely applicable strategy for pharmacogenomic discovery without the requirement for a

118 aced to make more important contributions to pharmacogenomic discovery.See related article by Mer et

119 ients is very challenging; thus, most cancer pharmacogenomics discovery is conducted in preclinical s

120 to review the state of research on metformin pharmacogenomics, discuss the scientific and clinical hu

121 ses, dermatology, clinical pharmacology, and pharmacogenomics discussed the current state of drug all

122 t for therapies based on molecular genetics (pharmacogenomics, DNA microarrays, etc.) drives pharmace

123 Pharmacogenomic drug challenge studies may be an especia

124 approach to explore mechanisms of action of pharmacogenomic effects and extend the field beyond obse

125 For this we used dose-response data from pharmacogenomic encyclopedias and represent these as a d

126 The "omics"-genomics, pharmacogenomics, epigenomics, proteomics, metabolomics,

127 Americans and 167 African Americans from the Pharmacogenomic Evaluation and Antihypertensive Response

128 ropean American participants enrolled in the Pharmacogenomic Evaluation of Antihypertensive Responses

129 ns (AA) and European Americans (EA) from the Pharmacogenomic Evaluation of Antihypertensive Responses

130 lower quartile of BP response to TD from the Pharmacogenomic Evaluation of Antihypertensive Responses

131 We conducted a pharmacogenomic evaluation using a genome-wide approach

132 Our results provided novel pharmacogenomic evidence to support the role of HTR7 in

133 RECENT FINDINGS: As the field of pharmacogenomics expands, more and more candidate genes

134 is of immediate use for prioritizing cancer pharmacogenomics experiments, and recovers known clinica

135 Guidance based on the most well-established pharmacogenomic findings has appeared in prescribing lab

136 abases, burden of inherited disease risk and pharmacogenomic findings, and burden and interrater agre

137 dult-onset disease risk, carrier status, and pharmacogenomics findings from nGS of 159 newborns in th

138 The rapidly expanding field of pharmacogenomics focuses on the genetic contributions to

139 t the opportunities for drug repurposing and pharmacogenomics for the treatment of hypertension.

140 In the case of pharmacogenomics, for instance, variants of consequence

141 understanding of cellular protein complexes, pharmacogenomics, genetic diagnosis and gene therapies.

142 We address the relevance of epigenetics, pharmacogenomics, genetic testing and counseling, and th

143 pressed before and after IMiD exposure using pharmacogenomic GEP data from patients who had bone marr

144 ensitive responders >/=65 years old required pharmacogenomic-guided protocols to achieve well-control

145 guided protocol, and 3 increasingly complex pharmacogenomic-guided protocols.

146 al clinical impact and cost-effectiveness of pharmacogenomic-guided therapy (PGT) are unknown.

147 Clinical trials testing pharmacogenomic-guided warfarin dosing for patients with

148 Pharmacogenomics has employed candidate gene studies and

149 However, pharmacogenomics has made only a few inroads into clinic

150 The field of pharmacogenomics has seen some exciting advances in the

151 Pharmacogenetics and, more recently, pharmacogenomics have been applied to the field of ADRs

152 Pharmacogenomics holds great promise for the development

153 to leukemogenesis, drug resistance, and host pharmacogenomics, identified novel subtypes of leukemia,

154 Important associations of pharmacogenomics in cardiovascular medicine include clop

155 olizing enzymes, genetic susceptibility, and pharmacogenomics in determining cardiovascular disease r

156 review will discuss recent investigations of pharmacogenomics in heart failure, and the challenge of

157 udy was conducted to investigate the role of pharmacogenomics in NCPH in HIV patients with prior dida

158 ay for clinical studies assessing the use of pharmacogenomics in the clinical management of patients

159 the prospective study of population-related pharmacogenomics in which ethnic differences in antineop

160 rs, the status of molecular drug targets and pharmacogenomic influences.

161 We have also incorporated pharmacogenomic information into our analyses.

162 portant for determining the applicability of pharmacogenomic information to medical practice.

163 tion, variant density across the genome, and pharmacogenomic information.

164 Human association studies showed a pharmacogenomic interaction between GRK5-Leu41 and beta-

165 further reported a kinome-wide landscape of pharmacogenomic interactions by incorporating somatic mu

166 e part of the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-ethnicity (SAPPHIRE

167 als from the Study for Asthma Phenotypes and Pharmacogenomic Interactions by Race-ethnicity (SAPPHIRE

168 e part of the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-ethnicity (SAPPHIRE

169 ants from the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE

170 To characterize the landscape of pharmacogenomic interactions in liver cancers, we develo

171 also uncover 1024 potential synthetic lethal pharmacogenomic interactions.

172 d the first steps towards the integration of pharmacogenomics into clinical practice.

173 e polymorphism association studies in muscle pharmacogenomics is a field of expected future growth.

174 Nevertheless, the importance of pharmacogenomics is likely to increase as the cost of dr

175 The impact of host pharmacogenomics is outlined.

176 The promise of pharmacogenomics is that it will one day result in targe

177 Pharmacogenomics is the study of how human genetic infor

178 Pharmacogenomics is the study of the inherited basis of

179 One of the goals of pharmacogenomics is the use of genetic variants to predi

180 Because one of the goals of pharmacogenomics is to identify individuals and target p

181 The goal of the emerging discipline of pharmacogenomics is to personalize therapy based on an i

182 Knowledge in pharmacogenomics is typically composed of units that hav

183 The behavioural impact of pharmacogenomics is untested.

184 This field, called pharmacogenomics, is a key area in the development of pr

185 Through increased knowledge in the area of pharmacogenomics, it is hoped that that treatment of pai

186 named kinome-wide network module for cancer pharmacogenomics (KNMPx), for identifying actionable mut

187 emonstrate that the DANs represent a systems pharmacogenomic landscape of drugs summarizing the entir

188 Interrogation of the pharmacogenomic landscape of LIMORE discovered unexplore

189 a(1)AR), a beta-blocker target, as candidate pharmacogenomic loci.

190 bitors, highlighting a potentially important pharmacogenomic marker to predict sensitivity to rapamyc

191 applying this information to uncover useful pharmacogenomic markers is uncertain.

192 Newly identified pharmacogenomic markers may be the first step in tailori

193 acid disposition; results also suggest that pharmacogenomic markers may be useful to identify patien

194 Importantly, combining existing pharmacogenomic markers with TF activities often improve

195 rs, biomarkers, advanced cardiac imaging and pharmacogenomics may be used to classify patients at ris

196 Our data also highlight a potentially novel pharmacogenomic mechanism related to response to acampro

197 s to clinical pharmacogenomic studies and to pharmacogenomic model systems that vary from cell line-b

198 In the pharmacokinetic-pharmacogenomic model, clearance was expected to increas

199 was performed to develop the pharmacokinetic-pharmacogenomic model.

200 was performed to develop the pharmacokinetic-pharmacogenomic model.

201 The study highlights the utility of pharmacogenomic monitoring to track patient responsivene

202 spective study was performed by the Canadian Pharmacogenomics Network for Drug Safety using patients

203 n's Hospital, Memphis, TN) who discussed the pharmacogenomics of acute lymphoblastic leukemia as a ca

204 elet therapy in individuals (n=565) from the Pharmacogenomics of Anti-Platelet Intervention (PAPI) St

205 sease (epilepsy), genomics of drug response (pharmacogenomics of antiepileptic drugs) and genomics of

206 DESIGN, SETTING, AND PARTICIPANTS: In the Pharmacogenomics of Antiplatelet Intervention (PAPI) Stu

207 last year that address the pathogenesis and pharmacogenomics of asthma.

208 o model basic tumor biology and to study the pharmacogenomics of BCa.

209 ct of buprenorphine treatment, including the pharmacogenomics of buprenorphine response and treatment

210 gations of minimal residual disease and host pharmacogenomics, offer promising avenues of research.

211 expression), response to treatment, and host pharmacogenomics offers the potential to enhance or supp

212 icacy of ADT, establishing the importance of pharmacogenomics on individual's response to this therap

213 ern the potential role of population-related pharmacogenomics (PG) in outcomes, we conducted a large

214 Pharmacogenetic/pharmacogenomic (PGx) approaches to psychopharmacology a

215 ciated with monogenic conditions, as well as pharmacogenomic (PGx) markers, blood antigen serotyping,

216 Pharmacogenomics (PGx) is the concept that treatments ca

217 Pharmacogenomics (PGx) studies how genomic variations im

218 ct may be combined in the determination of a pharmacogenomic phenotype and considering these polygeni

219 influence of rare versus common variants on pharmacogenomic phenotypes remains largely unexplored.

220 Here, we describe a pharmacogenomic platform that facilitates rapid discover

221 ccurate local ancestry analysis in genetics, pharmacogenomics, population genetics, and clinical diag

222 A 30-probe set pharmacogenomic predictor predicted pCR to T/FAC chemoth

223 for which ADR risk can be modified based on pharmacogenomic prescribing guidance.

224 By analyzing drug pharmacogenomics profiles from the Genomics of Drug Sens

225 In this study, we used pharmacogenomic profiling data provided from two indepen

226 nal complexity of cancer genomes, systematic pharmacogenomic profiling in cancer cell lines provides

227 tant example of the usefulness of additional pharmacogenomic profiling of pre-existing drugs for nove

228 ctronic Medical Records and Genomics Network Pharmacogenomics project from 7 US academic medical cent

229 omics, structural genomics, transcriptomics, pharmacogenomics, proteomics and metabolomics, allows fo

230 Pharmacogenomics provides the potential to unveil herita

231 ining patients from Henry Ford Heart Failure Pharmacogenomic Registry (n=247), the TIME-CHF (Trial of

232 andom subset of the Henry Ford Heart Failure Pharmacogenomic Registry (n=248) and then validated in a

233 ormance against manually-curated sets of (1) pharmacogenomic relationships from PharmGKB and (2) drug

234 ll have implications for pharmacogenetic and pharmacogenomic research and drug discovery.

235 ications of our model in pharmacogenetic and pharmacogenomic research are discussed.

236 plication of a pharmacometabolomics-informed pharmacogenomic research strategy, followed by functiona

237 ective tool in future clinical screening and pharmacogenomic research where more expensive fluorescen

238 HR-linked DNA biobanks to enable genomic and pharmacogenomic research, using EHR data for phenotypic

239 better phenotyping of research subjects, and pharmacogenomic research.

240 ere to assess the feasibility of prospective pharmacogenomics research in multicenter international c

241 The Pharmacogenomics Research Network and the Clinical Pharm

242 We used a pharmacometabolomics-informed pharmacogenomics research strategy to identify genes ass

243 iew describes some of the recent advances in pharmacogenomics research.

244 llMiner and CellMinerCDB and is an important pharmacogenomics resource for the field.

245 f state-of-the-art DL methods and up-to-date pharmacogenomics resources and future opportunities and

246 rapy in 768 hypertensive participants in the Pharmacogenomics Responses of Antihypertensive Responses

247 These pharmacogenomic results identify a genetic factor associ

248 Pharmacogenomic screening of an additional approximately

249 nce remains unclear on the potential role of pharmacogenomic screening prior to anthracycline therapy

250 For both diseases, large-scale pharmacogenomic screens of molecularly characterized sam

251 Notably, pharmacoproteomic and pharmacogenomic screens revealed that persisters are vul

252 enabling resources for the nascent field of pharmacogenomics (see Glossary), which tests the idea th

253 The field of pharmacogenomics seeks to identify genetic factors that

254 viduals with moderate AMD could benefit from pharmacogenomic selection of nutritional supplements.

255 ega-3 fatty acids), providing a means toward pharmacogenomics stratification of patients and monitori

256 tablish a generalizable method for exploring pharmacogenomics, structure and function across broad cl

257 cation of genome-wide techniques to clinical pharmacogenomic studies and to pharmacogenomic model sys

258 Pharmacogenomic studies are rapidly elucidating the inhe

259 ynonymous SNPs are often disregarded in many pharmacogenomic studies based on the assumption that the

260 Pharmacogenomic studies evaluating cardiac function in B

261 ance is a cause of chemotherapy failure, and pharmacogenomic studies have begun to define gene variat

262 for patients with persistent asthma, few ICS pharmacogenomic studies have involved nonwhite populatio

263 e results by integrating pharmacodynamic and pharmacogenomic studies in individualizing therapy for c

264 Pharmacogenomic studies of antipsychotics have typically

265 plications for diagnosis and future clinical pharmacogenomic studies of antitumor therapies.

266 the aromatase gene, CYP19, as a step toward pharmacogenomic studies of aromatase inhibitors.

267 it possible to perform molecular genetic and pharmacogenomic studies of these sulfate-conjugating enz

268 Two large-scale pharmacogenomic studies were published recently in this

269 Pharmacogenomic studies with microarrays showed that pro

270 anations as to why there is a discrepancy in pharmacogenomic studies, given recent concerns with poor

271 rful resource for pre-clinical breast cancer pharmacogenomic studies, including identification of bio

272 cell lines may be useful models for further pharmacogenomic studies.

273 serve as targets for medical, diagnostic, or pharmacogenomic studies.

274 Here, we summarize the recent pharmacogenomics studies in immunotherapy responsiveness

275 In the pharmacogenomic study (13,544 individuals with 44,618 di

276 chanisms in cancer treatment, we conducted a pharmacogenomic study using 266 lymphoblastoid cell line

277 ent weighting as a covariate, whereas in the pharmacogenomic study, HRs were adjusted for age, sex, h

278 This comprehensive pharmacogenomics study showed that individuals with the

279 ate chemosensitivity data from a large-scale pharmacogenomics study with basal gene expression data f

280 TPMT is a major pharmacogenomic target with 23 alleles identified to dat

281 (The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical C

282 Samples for pharmacokinetic and pharmacogenomic testing were obtained.

283 Common and classic features of pharmacogenomics that are related to both antiretroviral

284 utine sample storage and processing has made pharmacogenomics the most widely applied discovery-based

285 colleagues took a different approach: using pharmacogenomics to focus on neural stem cell lineage, t

286 PMT polymorphism illustrate the potential of pharmacogenomics to optimize cancer therapy by avoiding

287 Advances in the clinical application of pharmacogenomics to predict response to oncology therape

288 HIV and cancer medicine have used pharmacogenomics to some extent in clinical care.

289 action is formulated based on pharmacologic, pharmacogenomic, transcriptomic, and phenotypic data rel

290 ial genetic influence on LDL concentrations, pharmacogenomic trials have failed to identify genetic v

291 genotyping may be required to define cancer pharmacogenomics unequivocally.

292 e processes required to appropriately act on pharmacogenomic variability in the clinic are moving awa

293 While the discovery of pharmacogenomic variants of clozapine metabolism may imp

294 Carrier status for recessive diseases and pharmacogenomics variants were reported in 88% and 5% of

295 Pharmacogenomics will have an increasing role in the tre

296 rogress in the field of pharmacogenetics and pharmacogenomics will help further our understanding of

297 A better understanding of pharmacogenomics will optimize the current treatment sel

298 By resolving these hurdles, pharmacogenomics will yield significant, but incremental

299 germline genetics analysis methods to cancer pharmacogenomics with a focus on the special considerati

300 with a focus on monogenetic traits to become pharmacogenomics, with a genome-wide perspective.